<DOC>
	<DOCNO>NCT01195714</DOCNO>
	<brief_summary>This study multicentric , phase II , open-label , non-randomized trial evaluate efficacy O-miniCHOP patient age 80 year non previously treat CD20+ diffuse large B-cell lymphoma ( age-adjusted IPI=0 to3 ) , stage I , II , III IV performance status ECOG 0 4 . The anticipated study date ( start / end ) : 2010 - 2013 . The study evaluate cohort 120 patient ( approximately 95 France , 15 Belgium , 5 Switzerland 5 Portugal ) . Patients recruit 30 month follow least one year last patient include . The duration treatment period approximately 20 week .</brief_summary>
	<brief_title>Study Mini-Chop Plus Ofatumumab To Treat Cd 20+ Diffuse Large B-Cell Lymphoma In Patients Aged Over 80 Years</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patient histologically proven CD20+ diffuse large Bcell lymphoma ( DLBCL ) ( WHO classification 2008 ) include clinical subtypes ( primitive mediastinal , intravascular , etc . ) May also include : de Novo Transformed DLBCL low grade lymphoma ( Follicular , ... ) DLBCL associate small cell infiltration bone marrow Or CD20+ Bcell lymphoma , intermediate feature DLBCL Burkitt intermediate feature DLBCL classical Hodgkin lymphoma Or CD20+ Follicular lymphoma grade 3B Or CD20+ Aggressive Bcell lymphoma unclassifiable Aged 80 year . Ann Arbor stage I , II , III IV . All aaIPI Patient non previously treat . All ECOG performance status With minimum life expectancy 3 month . Negative HIV , HBV HCV serologies test &lt; 4 week ( except vaccination ) . Patient able give consent previously sign write informed consent . Patient affiliate social security system , applicable Any histological type lymphoma , Burkitt include . Any history treat nontreated smallB cell lymphoma . Central nervous system meningeal involvement lymphoma . Contraindication drug contain chemotherapy regimen . Any serious active disease ( accord investigator 's decision ) . Poor renal function ( creatinin level &gt; 150Âµmol/l ) , poor hepatic function ( total bilirubin level &gt; 30mmol/l , transaminase &gt; 2.5 maximum normal level ) unless abnormality relate lymphoma . Poor bone marrow reserve define neutrophil &lt; 1.5 G/l platelet &lt; 100 G/l , unless relate bone marrow infiltration . Any history cancer last 5 year exception nonmelanoma skin tumor stage 0 ( situ ) cervical carcinoma . Patients previously diagnose prostate cancer eligible ( 1 ) disease T1T2a , N0 , M0 , Gleason score &lt; 7 , prostate specific antigen ( PSA ) &lt; 10 ng/mL prior initial therapy , ( 2 ) definitive curative therapy ( ie , prostatectomy radiotherapy ) &gt; 2 year Day 1 Cycle 1 , ( 3 ) minimum 2 year follow therapy clinical evidence prostate cancer , PSA undetectable underwent prostatectomy &lt; 1 ng/mL undergo prostatectomy . Treatment investigational drug within 30 day plan first cycle chemotherapy study . Prior treatment antiCD20 monoclonal antibody alemtuzumab within 3 month prior start therapy Adult patient tutelage .</criteria>
	<gender>All</gender>
	<minimum_age>81 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>